Clinical trial
Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy as First Line…
NCT00095394 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00095394 |
|---|---|
| Title | Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy as First Line Treatment for Severe Hypertension |
| Official title | The Efficacy and Safety of Irbesartan/HCTZ Combination Therapy as First Line Treatment for Severe Hypertension |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Collaborators | Sanofi Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hypertension |
| Intervention type | Drug |
| Interventions | Irbesartan/HCTZ, Irbesartan monotherapy |
| Enrollment | 645 |
| Start date | Sep 1, 2004 |
| Primary completion | May 1, 2005 |
| Completion | May 1, 2005 |
| First posted | Nov 4, 2004 |
| Last update posted | Apr 15, 2011 |
| Countries | Belgium, Canada, France, Germany, Israel, Netherlands, Russia, United States |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: